NO324708B1 - Sammensetning og doseform som omfatter multipotente neurale stamceller, unntatt embryoniske stamceller, samt anvendelse av mammalske multipotente neuralstamcelle-etterkommere. - Google Patents

Sammensetning og doseform som omfatter multipotente neurale stamceller, unntatt embryoniske stamceller, samt anvendelse av mammalske multipotente neuralstamcelle-etterkommere. Download PDF

Info

Publication number: NO324708B1
Authority: NO; Norway
Prior art keywords: cells; neural stem; hematopoietic; multipotent neural; mnsc
Prior art date: 1997-09-29

Application number

NO20001509A

Other languages

English (en)

Norwegian (no)

Other versions

NO20001509D0 (no

NO20001509L (no

Inventor

Christopher R Bjornson

Rod L Rietze

Brent A Reynolds

Angelo L Vescovi

Original Assignee

Neurospheres Holdings Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-29

Filing date

2000-03-23

Publication date

2007-12-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26739784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324708(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-23 Application filed by Neurospheres Holdings Ltd filed Critical Neurospheres Holdings Ltd

2000-03-23 Publication of NO20001509D0 publication Critical patent/NO20001509D0/no

2000-05-23 Publication of NO20001509L publication Critical patent/NO20001509L/no

2007-12-03 Publication of NO324708B1 publication Critical patent/NO324708B1/no

Links

210000001178 neural stem cell Anatomy 0.000 title claims abstract description 63
239000000203 mixture Substances 0.000 title claims description 18
239000002552 dosage form Substances 0.000 title claims description 5
210000001671 embryonic stem cell Anatomy 0.000 title claims description 5
210000004027 cell Anatomy 0.000 claims abstract description 152
210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 56
210000000777 hematopoietic system Anatomy 0.000 claims abstract description 41
230000003394 haemopoietic effect Effects 0.000 claims abstract description 23
241000124008 Mammalia Species 0.000 claims abstract description 10
230000000735 allogeneic effect Effects 0.000 claims abstract description 5
241001465754 Metazoa Species 0.000 claims description 59
210000001519 tissue Anatomy 0.000 claims description 41
230000001537 neural effect Effects 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 13
230000015572 biosynthetic process Effects 0.000 claims description 8
239000003102 growth factor Substances 0.000 claims description 8
239000000243 solution Substances 0.000 claims description 8
206010028980 Neoplasm Diseases 0.000 claims description 6
230000009395 genetic defect Effects 0.000 claims description 6
239000002243 precursor Substances 0.000 claims description 6
208000007056 sickle cell anemia Diseases 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 4
210000000987 immune system Anatomy 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
208000032467 Aplastic anaemia Diseases 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 3
230000037396 body weight Effects 0.000 claims description 3
210000003169 central nervous system Anatomy 0.000 claims description 3
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
230000000366 juvenile effect Effects 0.000 claims description 3
208000002865 osteopetrosis Diseases 0.000 claims description 3
241000237970 Conus <genus> Species 0.000 claims description 2
210000000133 brain stem Anatomy 0.000 claims description 2
210000001638 cerebellum Anatomy 0.000 claims description 2
210000003710 cerebral cortex Anatomy 0.000 claims description 2
210000003754 fetus Anatomy 0.000 claims description 2
210000001652 frontal lobe Anatomy 0.000 claims description 2
238000010253 intravenous injection Methods 0.000 claims description 2
210000001259 mesencephalon Anatomy 0.000 claims description 2
210000000278 spinal cord Anatomy 0.000 claims description 2
210000003016 hypothalamus Anatomy 0.000 claims 1
238000002054 transplantation Methods 0.000 abstract description 29
210000004369 blood Anatomy 0.000 abstract description 15
239000008280 blood Substances 0.000 abstract description 15
238000001727 in vivo Methods 0.000 abstract description 8
230000001939 inductive effect Effects 0.000 abstract description 6
238000010322 bone marrow transplantation Methods 0.000 abstract description 5
238000011134 hematopoietic stem cell transplantation Methods 0.000 abstract description 4
230000000295 complement effect Effects 0.000 abstract description 3
238000000034 method Methods 0.000 description 59
241000699670 Mus sp. Species 0.000 description 32
210000001185 bone marrow Anatomy 0.000 description 30
210000000130 stem cell Anatomy 0.000 description 30
238000000338 in vitro Methods 0.000 description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 11
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 10
210000005259 peripheral blood Anatomy 0.000 description 10
239000011886 peripheral blood Substances 0.000 description 10
238000002512 chemotherapy Methods 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
210000000952 spleen Anatomy 0.000 description 9
235000011449 Rosa Nutrition 0.000 description 8
238000000684 flow cytometry Methods 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
239000002609 medium Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 7
238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
238000001802 infusion Methods 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
238000001574 biopsy Methods 0.000 description 6
210000000601 blood cell Anatomy 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000006285 cell suspension Substances 0.000 description 6
238000001514 detection method Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
238000001959 radiotherapy Methods 0.000 description 6
230000008901 benefit Effects 0.000 description 5
210000002798 bone marrow cell Anatomy 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
210000001541 thymus gland Anatomy 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
101150066555 lacZ gene Proteins 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
241000894007 species Species 0.000 description 4
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
108700028369 Alleles Proteins 0.000 description 3
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
208000026350 Inborn Genetic disease Diseases 0.000 description 3
102100022338 Integrin alpha-M Human genes 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
238000011316 allogeneic transplantation Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
102000005936 beta-Galactosidase Human genes 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
238000011124 ex vivo culture Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
208000016361 genetic disease Diseases 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
208000024908 graft versus host disease Diseases 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
238000003306 harvesting Methods 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
229940124589 immunosuppressive drug Drugs 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000013642 negative control Substances 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
208000010648 susceptibility to HIV infection Diseases 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
230000035899 viability Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
102000009024 Epidermal Growth Factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
108010002386 Interleukin-3 Proteins 0.000 description 2
102000000646 Interleukin-3 Human genes 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
210000001130 astrocyte Anatomy 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000032823 cell division Effects 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
238000009643 clonogenic assay Methods 0.000 description 2
231100000096 clonogenic assay Toxicity 0.000 description 2
230000002338 cryopreservative effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
210000004700 fetal blood Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000000799 fluorescence microscopy Methods 0.000 description 2
238000012239 gene modification Methods 0.000 description 2
230000005017 genetic modification Effects 0.000 description 2
235000013617 genetically modified food Nutrition 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
210000003519 mature b lymphocyte Anatomy 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
210000004248 oligodendroglia Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000002629 repopulating effect Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000012224 working solution Substances 0.000 description 2
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101150017501 CCR5 gene Proteins 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108050000299 Chemokine receptor Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000035240 Disease Resistance Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
208000015872 Gaucher disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
102000000704 Interleukin-7 Human genes 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108010064983 Ovomucin Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229930195708 Penicillin V Natural products 0.000 description 1
206010061924 Pulmonary toxicity Diseases 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
101000930457 Rattus norvegicus Albumin Proteins 0.000 description 1
208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010043391 Thalassaemia beta Diseases 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
231100000987 absorbed dose Toxicity 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
210000004504 adult stem cell Anatomy 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000003181 biological factor Substances 0.000 description 1
210000000625 blastula Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
VIEXQFHKRAHTQS-UHFFFAOYSA-N chloroselanyl selenohypochlorite Chemical compound Cl[Se][Se]Cl VIEXQFHKRAHTQS-UHFFFAOYSA-N 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000009193 crawling Effects 0.000 description 1
238000012364 cultivation method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
210000002451 diencephalon Anatomy 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940100994 interleukin-7 Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000004899 motility Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
210000005155 neural progenitor cell Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229940124585 oral penicillin Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000002135 phase contrast microscopy Methods 0.000 description 1
HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
231100000374 pneumotoxicity Toxicity 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000003133 propidium iodide exclusion Methods 0.000 description 1
230000007047 pulmonary toxicity Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
101150069452 z gene Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Developmental Biology & Embryology (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Materials For Medical Uses (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20001509A 1997-09-29 2000-03-23 Sammensetning og doseform som omfatter multipotente neurale stamceller, unntatt embryoniske stamceller, samt anvendelse av mammalske multipotente neuralstamcelle-etterkommere. NO324708B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US6028997P	1997-09-29	1997-09-29
US09/100,679 US6093531A (en)	1997-09-29	1998-06-19	Generation of hematopoietic cells from multipotent neural stem cells
PCT/CA1998/000916 WO1999016863A1 (en)	1997-09-29	1998-09-28	Generation of hematopoietic cells from multipotent neural stem cells

Publications (3)

Publication Number	Publication Date
NO20001509D0 NO20001509D0 (no)	2000-03-23
NO20001509L NO20001509L (no)	2000-05-23
NO324708B1 true NO324708B1 (no)	2007-12-03

Family

ID=26739784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20001509A NO324708B1 (no)	1997-09-29	2000-03-23	Sammensetning og doseform som omfatter multipotente neurale stamceller, unntatt embryoniske stamceller, samt anvendelse av mammalske multipotente neuralstamcelle-etterkommere.

Country Status (11)

Country	Link
US (3)	US6093531A (de)
EP (1)	EP1019493B1 (de)
JP (1)	JP2001518289A (de)
AT (1)	ATE310077T1 (de)
AU (1)	AU9249598A (de)
CA (1)	CA2304007A1 (de)
DE (1)	DE69832402T2 (de)
DK (1)	DK1019493T3 (de)
ES (1)	ES2255179T3 (de)
NO (1)	NO324708B1 (de)
WO (1)	WO1999016863A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6787355B1 (en)	1996-08-26	2004-09-07	Mcgill University	Multipotent neural stem cells from peripheral tissues and uses thereof
US7795202B2 (en) *	1997-08-04	2010-09-14	Neurorepair, Inc.	Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US7790669B1 (en)	1997-08-04	2010-09-07	Neurorepair, Inc.	Methods for treating neurological deficits by intrastriatal administration of transforming growth factor alpha (TGF-α)
US20010007657A1 (en) *	1997-08-04	2001-07-12	Reid James Steven	Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
US20020016002A1 (en) *	2000-01-24	2002-02-07	Jean Toma	Multipotent neural stem cells from peripheral tissues and uses thereof
US20020123143A1 (en) *	1997-08-22	2002-09-05	Jean Toma	Multipotent stem cells from peripheral tissues and uses thereof
US6638501B1 (en) *	1997-09-29	2003-10-28	Neurospheres Holdings Ltd.	Use of multipotent neural stem cell progeny to augment non-neural tissues
US6093531A (en) *	1997-09-29	2000-07-25	Neurospheres Holdings Ltd.	Generation of hematopoietic cells from multipotent neural stem cells
US6541247B1 (en)	1998-06-25	2003-04-01	Neuronova Ab	Method of isolating ependymal neural stem cells
SE9802264D0 (sv)	1998-06-25	1998-06-25	Neuronova Ab	A method of isolating cells
ATE514772T1 (de)	1999-08-05	2011-07-15	Abt Holding Co	Multipotente erwachsene stammzellen und verfahren zu deren isolierung
US8609412B2 (en)	1999-08-05	2013-12-17	Regents Of The University Of Minnesota	Mapc generation of lung tissue
US8075881B2 (en)	1999-08-05	2011-12-13	Regents Of The University Of Minnesota	Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US7015037B1 (en)	1999-08-05	2006-03-21	Regents Of The University Of Minnesota	Multiponent adult stem cells and methods for isolation
US8252280B1 (en)	1999-08-05	2012-08-28	Regents Of The University Of Minnesota	MAPC generation of muscle
US10638734B2 (en)	2004-01-05	2020-05-05	Abt Holding Company	Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
AU2001234998B2 (en) *	2000-02-11	2006-06-08	Childrens Hospital Of Orange County A California Corporation	Isolation and transplantation of retinal stem cells
AU2001284923A1 (en) *	2000-08-15	2002-02-25	Geron Corporation	Reprogramming cells for enhanced differentiation capacity using pluripotent stemcells
US7311905B2 (en)	2002-02-13	2007-12-25	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da)	2000-12-06	2014-11-10	Anthrogenesis Corp	Fremgangsmåde til indsamling af stamceller fra moderkagen
IL157350A0 (en)	2001-02-14	2004-02-19	Anthrogenesis Corp	Post-partum mammalian placenta, its use and placental stem cells therefrom
EP1367899A4 (de)	2001-02-14	2004-07-28	Leo T Furcht	Multipotente adulte stammzellen, ausgangsmaterial dafür, verfahren zu ihrer gewinnung und erhaltung, differenzierungsmethoden dafür, verfahren zu ihrer verwendung, sowie von ihnen stammende zellen
US7838292B1 (en)	2001-03-29	2010-11-23	University Of Louisville Research Foundation, Inc.	Methods for obtaining adult human olfactory progenitor cells
US20030017587A1 (en) *	2001-07-18	2003-01-23	Rader William C.	Embryonic stem cells, clinical applications and methods for expanding in vitro
US20030211603A1 (en) *	2001-08-14	2003-11-13	Earp David J.	Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US20050064587A1 (en) *	2001-09-07	2005-03-24	Lawrence Rosenberg	Pancreatic small cells and uses thereof
US20030099621A1 (en) *	2001-11-29	2003-05-29	Robert Chow	Stem cell screening and transplantation therapy for HIV infection
DE10162080A1 (de) *	2001-12-10	2003-06-26	Albrecht Mueller	Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
CA2473115A1 (en) *	2002-01-09	2003-07-24	Japan Science And Technology Agency	Remedy for dysmnesia
WO2003080818A1 (en) *	2002-03-27	2003-10-02	Institute Of Gene And Brain Science	Method of inducing growth of nerve stem cells
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2488013A1 (en) *	2002-05-30	2003-12-11	Celgene Corporation	Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
CA2492542A1 (en) *	2002-07-30	2004-02-05	Stem Cell Therapeutics Inc.	Oligodendrocyte production from multipotent neural stem cells
JP2006509770A (ja)	2002-11-26	2006-03-23	アンソロジェネシスコーポレーション	細胞治療学、細胞治療単位、およびそれらを利用した治療法
US20060228798A1 (en)	2002-11-27	2006-10-12	Catherine Verfaillie	Homologous recombination in multipotent adult progenitor cells
US20040219608A1 (en) *	2003-04-29	2004-11-04	Der-Balian Georges Puzant	Method of cell analysis using small volume of blood
DE602004030809D1 (de) *	2003-09-12	2011-02-10	Stemcell Technologies Inc	Test für neurale koloniebildung
US8187875B2 (en) *	2004-02-26	2012-05-29	Reliance Life Sciences Pvt. Ltd.	Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof
US8685724B2 (en) *	2004-06-01	2014-04-01	Kwalata Trading Limited	In vitro techniques for use with stem cells
US20060110374A1 (en) *	2004-11-24	2006-05-25	Dudy Czeiger	Method to accelerate stem cell recruitment and homing
AU2006304277B2 (en)	2005-10-13	2012-07-05	Celularity Inc.	Immunomodulation using placental stem cells
JP2009511061A (ja)	2005-10-14	2009-03-19	リージェンツオブザユニバーシティオブミネソタ	膵臓表現型を有する細胞への非胚性幹細胞の分化
US8404653B2 (en) *	2005-11-14	2013-03-26	Enterprise Partners Venture Capital	Membrane bound stem cell factor therapy for ischemic heart
US8455250B2 (en)	2005-12-29	2013-06-04	Anthrogenesis Corporation	Co-culture of placental stem cells and stem cells from a second source
ES2671355T3 (es)	2005-12-29	2018-06-06	Anthrogenesis Corporation	Poblaciones de células madre placentarias
TW200734462A (en)	2006-03-08	2007-09-16	In Motion Invest Ltd	Regulating stem cells
KR100838013B1 (ko) *	2006-06-07	2008-06-12	제일약품주식회사	인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법
CA2655990A1 (en) *	2006-06-22	2007-12-27	Tai June Yoo	Restoration of hearing loss
WO2008063675A2 (en)	2006-11-24	2008-05-29	Regents Of The University Of Minnesota	Endodermal progenitor cells
CA2677273A1 (en) *	2007-02-06	2008-08-14	Tai-June Yoo	Use of a composition comprising a cytokine encoding nucleic acid for treating alzheimer's disease
SI2120977T1 (sl)	2007-02-12	2014-01-31	Anthrogenesis Coroporation	Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
US20080233088A1 (en) *	2007-02-16	2008-09-25	Varian Medical Systems Technologies, Inc.	Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation
US20080219955A1 (en) *	2007-03-08	2008-09-11	Sekula Raymond F	Method of Producing Purified Neural Stem Cells and Related Methods of Treating a Patient
US8574567B2 (en) *	2007-05-03	2013-11-05	The Brigham And Women's Hospital, Inc.	Multipotent stem cells and uses thereof
WO2008137115A1 (en)	2007-05-03	2008-11-13	The Brigham And Women's Hospital, Inc.	Multipotent stem cells and uses thereof
US8617882B2 (en) *	2007-06-06	2013-12-31	The Hospital For Sick Children	Skin-derived precursor cells and uses thereof
US9200253B1 (en)	2007-08-06	2015-12-01	Anthrogenesis Corporation	Method of producing erythrocytes
RS53841B1 (sr)	2007-09-28	2015-06-30	Anthrogenesis Corporation	Supresija tumora korišćenjem humanog placentalnog perfuzata i intermedijernih ćelija ubica poreklom iz humane placente
AU2009205886B2 (en)	2008-01-18	2015-08-27	Katholieke Universiteit Leuven	Stem cell aggregates and methods for making and using
KR20180108887A (ko)	2008-08-20	2018-10-04	안트로제네시스 코포레이션	단리된 태반 세포를 사용한 뇌졸중 치료
DK2330889T3 (en)	2008-08-20	2017-01-30	Anthrogenesis Corp	Improved cell composition and process for making the same
MX2011001992A (es)	2008-08-22	2011-03-29	Anthrogenesis Corp	Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
US8748177B2 (en)	2008-09-30	2014-06-10	The Hospital For Sick Children	Compositions for proliferation of cells and related methods
US9057051B2 (en)	2008-10-31	2015-06-16	Katholieke Universiteit Leuven	Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells
CA2743566C (en)	2008-11-19	2021-11-09	Anthrogenesis Corporation	Amnion derived adherent cells
AR077369A1 (es)	2009-07-02	2011-08-24	Anthrogenesis Corp	Metodopara producir eritrocitos sin celulas alimentadoras
WO2011094181A1 (en)	2010-01-26	2011-08-04	Anthrogenesis Corporation	Treatment of bone-related cancers using placental stem cells
SI2556145T1 (sl)	2010-04-07	2017-01-31	Anthrogenesis Corporation	Angiogeneza z uporabo placentnih matičnih celic
AU2011237743A1 (en)	2010-04-08	2012-11-01	Anthrogenesis Corporation	Treatment of sarcoidosis using placental stem cells
SG10201913920PA (en)	2010-05-12	2020-03-30	Abt Holding Co	Modulation of splenocytes in cell therapy
US9090878B2 (en)	2010-06-17	2015-07-28	Katholieke Universiteit Leuven	Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
CN107828727A (zh)	2010-07-13	2018-03-23	人类起源公司	产生自然杀伤细胞的方法、由此获得的细胞群体及其用途
SG188280A1 (en)	2010-08-24	2013-04-30	Univ Minnesota	Non-static suspension culture of cell aggregates
RU2439147C1 (ru) *	2010-10-11	2012-01-10	Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН НИИ фармакологии СО РАМН	Способ стимуляции in vitro полипотентных гемопоэтических стволовых клеток
AR093183A1 (es)	2010-12-31	2015-05-27	Anthrogenesis Corp	Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (de)	2011-06-01	2019-02-20	Celularity, Inc.	Schmerzbehandlung mithilfe von stammzellen aus der plazenta
WO2013055476A1 (en)	2011-09-09	2013-04-18	Anthrogenesis Corporation	Treatment of amyotrophic lateral sclerosis using placental stem cells
CA2864818C (en)	2012-02-17	2022-05-03	The Schepens Eye Research Institute	Phenotype profile of human retinal progenitor cells
AU2014215458A1 (en)	2013-02-05	2015-08-13	Anthrogenesis Corporation	Natural killer cells from placenta
IL289870B2 (en)	2013-04-12	2023-03-01	Lafrancesca Saverio	Improving organs for transplantation
FR3026744B1 (fr)	2014-10-06	2024-04-19	Hopitaux Paris Assist Publique	Methode de generation de progeniteurs de cellules t
BR112019016672A8 (pt)	2017-02-13	2022-11-22	Hopitaux Paris Assist Publique	Método para gerar progenitores de células t

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4714680B1 (en) *	1984-02-06	1995-06-27	Univ Johns Hopkins	Human stem cells
US5082670A (en) *	1988-12-15	1992-01-21	The Regents Of The University Of California	Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5437994A (en) *	1989-06-15	1995-08-01	Regents Of The University Of Michigan	Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5635386A (en) *	1989-06-15	1997-06-03	The Regents Of The University Of Michigan	Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5061620A (en) *	1990-03-30	1991-10-29	Systemix, Inc.	Human hematopoietic stem cell
WO1991018620A1 (en) *	1990-06-08	1991-12-12	New York University	Stimulation of bone marrow stromal and progenitor cells
US5618531A (en) *	1990-10-19	1997-04-08	New York University	Method for increasing the viability of cells which are administered to the brain or spinal cord
US6497872B1 (en) *	1991-07-08	2002-12-24	Neurospheres Holdings Ltd.	Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5750376A (en) *	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) *	1991-07-08	1998-12-22	Neurospheres, Ltd.	In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5589376A (en) *	1992-07-27	1996-12-31	California Institute Of Technology	Mammalian neural crest stem cells
US5766948A (en) *	1993-01-06	1998-06-16	The Regents Of The University Of California	Method for production of neuroblasts
US6432711B1 (en) *	1993-11-03	2002-08-13	Diacrin, Inc.	Embryonic stem cells capable of differentiating into desired cell lines
CN1141058A (zh) *	1993-11-09	1997-01-22	纽罗斯菲里斯控股有限公司	中枢神经系统干细胞的原位修饰和处理
US5591625A (en) *	1993-11-24	1997-01-07	Case Western Reserve University	Transduced mesenchymal stem cells
US5639618A (en) *	1994-05-13	1997-06-17	Plurion, Inc.	Method of isolating a lineage specific stem cell in vitro
EP0792350A1 (de) *	1994-11-14	1997-09-03	Neurospheres Holdings Ltd.	Proliferation regelung von neuralen stammzellen
US6890724B2 (en) *	1996-09-06	2005-05-10	California Institute Of Technology	Methods and compositions for neural progenitor cells
US5968829A (en) *	1997-09-05	1999-10-19	Cytotherapeutics, Inc.	Human CNS neural stem cells
US6638501B1 (en) *	1997-09-29	2003-10-28	Neurospheres Holdings Ltd.	Use of multipotent neural stem cell progeny to augment non-neural tissues
US6093531A (en) *	1997-09-29	2000-07-25	Neurospheres Holdings Ltd.	Generation of hematopoietic cells from multipotent neural stem cells

1998
- 1998-06-19 US US09/100,679 patent/US6093531A/en not_active Expired - Fee Related
- 1998-09-28 JP JP2000513934A patent/JP2001518289A/ja active Pending
- 1998-09-28 ES ES98944943T patent/ES2255179T3/es not_active Expired - Lifetime
- 1998-09-28 EP EP98944943A patent/EP1019493B1/de not_active Expired - Lifetime
- 1998-09-28 AU AU92495/98A patent/AU9249598A/en not_active Abandoned
- 1998-09-28 CA CA002304007A patent/CA2304007A1/en not_active Abandoned
- 1998-09-28 DK DK98944943T patent/DK1019493T3/da active
- 1998-09-28 DE DE69832402T patent/DE69832402T2/de not_active Expired - Fee Related
- 1998-09-28 WO PCT/CA1998/000916 patent/WO1999016863A1/en not_active Ceased
- 1998-09-28 AT AT98944943T patent/ATE310077T1/de not_active IP Right Cessation
2000
- 2000-03-23 NO NO20001509A patent/NO324708B1/no unknown
- 2000-07-24 US US09/624,199 patent/US6897060B1/en not_active Expired - Fee Related
2003
- 2003-02-21 US US10/371,779 patent/US7204979B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1019493B1 (de)	2005-11-16
EP1019493A1 (de)	2000-07-19
DE69832402T2 (de)	2006-08-10
CA2304007A1 (en)	1999-04-08
DE69832402D1 (de)	2005-12-22
US6897060B1 (en)	2005-05-24
US7204979B2 (en)	2007-04-17
US20030148515A1 (en)	2003-08-07
WO1999016863A1 (en)	1999-04-08
DK1019493T3 (da)	2006-04-03
US6093531A (en)	2000-07-25
NO20001509D0 (no)	2000-03-23
JP2001518289A (ja)	2001-10-16
NO20001509L (no)	2000-05-23
ATE310077T1 (de)	2005-12-15
ES2255179T3 (es)	2006-06-16
AU9249598A (en)	1999-04-23

Publication	Publication Date	Title
NO324708B1 (no)	2007-12-03	Sammensetning og doseform som omfatter multipotente neurale stamceller, unntatt embryoniske stamceller, samt anvendelse av mammalske multipotente neuralstamcelle-etterkommere.
DE69929681T2 (de)	2006-10-26	Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
TWI698527B (zh)	2020-07-11	利用血管母細胞產生間葉基質細胞之方法
JPH09507383A (ja)	1997-07-29	卵黄嚢幹細胞およびその使用
KR20080056302A (ko)	2008-06-20	태반 유래 줄기세포로부터 생산된 희소돌기 아교세포
KR101846464B1 (ko)	2018-04-09	외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물
US10092599B2 (en)	2018-10-09	Methods for enhancing hematopoietic stem/progenitor cell engraftment
US12415987B2 (en)	2025-09-16	Methods and composition for producing and using immune cells and stem cells for cell-based therapies
KR20090033328A (ko)	2009-04-02	면역 특권 및 조절 전구 세포
US10159697B2 (en)	2018-12-25	Methods for enhancing hematopoietic stem/progenitor cell engraftment
AU2003200256B2 (en)	2006-02-23	Generation of hematopoietic cells from multipotent neural stem cells
AU661709B2 (en)	1995-08-03	Yolk sac stem cells
US20110052545A1 (en)	2011-03-03	Regeneration system, its production and use
CA2617108A1 (en)	2007-02-08	Method for regenerating an immune system
Thompson	2014	Immunogenicity of Embryonic Stem Cell Derived Hematopoietic Progenitors
HK40009323B (en)	2024-02-16	Methods and composition for producing and using immune cells and stem cells for cell-based therapies
HK40009323A (en)	2020-06-26	Methods and composition for producing and using immune cells and stem cells for cell-based therapies